The 190 kD (p190) and 210 kD (p210) Bcr-Abl proteins are responsible for the pathophysiology of Philadelphia chromosome (Ph) þ leukemia. We applied RNA interference (RNAi) to specific killing of p190 þ cells, and determined the optimal sequences for gene silencing in the BCR, junctional and ABL regions of p190, respectively. Then, p190
Introduction
Philadelphia chromosome (Ph) þ leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (Ph þ ALL), originates from hematopoietic stem/progenitor cells affected by the BCR-ABL fusion gene, which encodes constitutively active tyrosine kinase essential for development and progression of the diseases. 1 There are two major forms of Bcr-Abl protein, p210 and p190. The former is associated with almost all cases of CML and less than half of Ph þ ALL cases, whereas the latter mainly causes Ph þ ALL except for very rare cases of CML. 2 The development of imatinib (also referred to as STI571), and the second generation tyrosine kinase inhibitors have greatly improved the clinical outcome of CML. [3] [4] [5] However, Ph þ ALL shows a much less durable response to these kinase inhibitors, and easily acquires resistance, caused primarily by point mutations in the Abl kinase domain such as T315I. 6, 7 To overcome the resistance, the downregulation of Bcr-Abl proteins is a promising strategy for eliminating Ph þ ALL cells, irrespective of point mutations. From this viewpoint, we have previously reported that lentiviral delivery of anti-p190 maxizyme specifically induces apoptosis in Ph þ ALL cells. 8 Recently, RNA interference (RNAi) has been recognized as a more powerful tool in the selective gene silencing. RNAi allows downregulation of target genes at the post-transcriptional level via sequence-specific mRNA depletion. This can be accomplished by the delivery of double-strand RNA in the form of small interfering RNA (siRNA) or small hairpin RNA (shRNA). 9, 10 Anti-p210 RNAi targeting sequences of the junctional domain of Bcr-Abl suppressed its expression in CML cell lines, resulting in growth inhibition, 11, 12 and lentivirus-mediated stable expression of anti-p210 shRNA has also been successful. 13, 14 Similarly, electroporation of p190 þ cells with anti-p190 siRNA downregulated p190 and reduced cell viability in a dosedependent fashion. 15 However, this procedure may exert nonspecific toxicity on intact cells, and short-lived siRNA is not suitable for monitoring cell viability. Therefore, to precisely evaluate the consequences of RNAi-mediated p190 silencing, viral vector-mediated transfer and stable expression of shRNA in p190 þ cells are required. In the present study, we successfully downregulated p190 by lentiviral transduction with shRNA targeting p190, resulting in efficiently killing of p190 þ cells. We also observed that silencing of p190 caused specific inactivation of Stat5 and cooperated with imatinib and 17-allylamino-17-demetoxygeldanamycin (17-AAG) in the selective killing of p190 þ cells.
Materials and methods

Design of shRNAs targeting p190
Three types of 21-bp shRNA were designed, and named as shE1A2, shABL and shBCR, respectively. shE1A2 targets junctional lesion between BCR exon 1 and ABL exon 2 (e1a2) in p190 mRNA. The sequence was determined after the screening by a transient transfection of 293/p190 cells with a series of U6-promoter driven shE1A2 expression vectors, in which we found that the center of junctional lesion was suitable for target site (Supplementary Figure 1) . We also designed shABL targeting nt 1238-1258 of ABL, and shBCR targeting nt 992-1012 of BCR, with a computer algorithm (iGENE Therapeutics, Tsukuba, Japan) to identify optimal sequences, and tested for their ability to downregulate p190 (Supplementary Figure 2) . shLUC targeting Renilla luciferase was prepared as a control. Although shE1A2 is supposed to be specific for p190, shABL is predicted to affect not only p190 but also p210 and Abl. Similarly, shBCR is predicted to affect p190, p210 as well as Bcr (Figures 1a and b) .
Production of lentiviral vectors
The nucleotide sequences of the shRNA expression cassette in the piGENE-PURhU6/shRNA were amplified by polymerase chain reaction using Platinum pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA) and a primer set containing a BamHI site (forward 5 0 -ATGGATCCAAGGTCGGGCAGGAAGAGG-3 0 and reverse 5 0 -ATGGATCCCATGATGATTACGCCAAGCTTGCAT-3 0 ). The resulting fragments were digested with BamHI and ligated into a BamHI-digested self-inactivating lentiviral transfer vector. The expression cassettes for shE1A2, shABL and shLUC were inserted into lentiviral transfer vector pCS-CDF-EG-PRE containing elongation factor 1a (EF1a) promoter-driven human CD2 as a selection marker (pHIV-CD2), and the shBCR expression cassette was inserted into a similar transfer vector containing CD271 as a marker (pHIV-CD271). Lentiviral vector particles were produced by cotransfection of 293T cells with pHIV-hU6/ shRNA, pMDLg/p.RRE, pRSV-rev and pMD.G as described previously. 16 Transduction efficiency was analyzed by flow cytometry of marker gene expression, resulting in 94-99% at high multiplicity of infection (MOI ¼ 5) and around 50% (36-59%) at low MOI (MOI ¼ 1).
Western blot analysis
Cells were lysed, and 50 mg of the lysate were electrophoresed in SDS-polyacrylamide gels, transferred onto polyvinylidene fluoride membranes, and blotted with the respective antibodies, according to the manufactures' instructions. All secondary antibodies were peroxidase-conjugated, and proteins were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). The following antibodies were used: anti-Abl (8E9; BD Biosciences, San Diego, CA, USA), antiBcr (N-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Jak2 (06-255; Upstate Biotechnology, Lake Placid, NY, USA), anti-phospho-Jak2 (Tyr1007/1008; Upstate Biotechnology), and anti-Stat5 (C-17; Santa Cruz Biotechnology); anti-phosphoStat5 (Tyr694), anti-Akt1, (2H10), anti-phospho-Akt (Ser473), anti-MEK1/2 (L38C12), anti-phospho-MEK1/2 (Ser221) (all from Cell Signaling Technology, Danvers, MA, USA); anti-Actin (AC-40; Sigma, St Louis, MO, USA), sheep anti-mouse IgG (515-036-072; Jacson ImmunoResearch Labolatories, West Grove, PA, USA) and donkey anti-rabbit IgG (NA934V; Amersham Biosciences, Little Chalfont, Bucks, UK). 
Cell count and viability assay
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Bcr-Abl number and viability were determined by trypan blue dye exclusion. For cell proliferation assay, 10 3 cells in 100 ml of culture medium were grown in a 96-multiwell plate. Viable cell number was assessed on day 4 using WST-8 assay kit (Seikagaku, Tokyo, Japan).
Colony-forming assay
Human CD34 þ cells were purified from umbilical cord blood mononuclear cells by a two-round separation procedure using the Indirect CD34 MicroBead Kit (Miltenyi Biotec, Auburn, CA, USA). Purified CD34 þ cells were cultured in a-minimal essential medium containing 30% fetal bovine serum (FBS), 50 ng ml À1 hSCF, 50 ng ml À1 hTPO, 10 ng ml À1 hIL-3 and 50 ng ml À1 Flt3L for 24 h, transduced with anti-p190 shRNA lentiviral vectors at an MOI of 20, and incubated for 48 h. Aliquots of 10 3 transduced cells were plated in triplicate in 1 ml of 0.9% methylcellulose containing 30% FBS, 50 ng ml À1 hSCF, 10 ng ml À1 hIL-3, 100 ng ml À1 hG-CSF, and 2 U ml À1 hEPO. After 14 days, the number of each type of colony was scored.
Results
Silencing effect of anti-p190 shRNA lentiviral vectors
To confirm the silencing effect, we transduced HEK 293/p190 cells with lentiviral vectors encoding anti-p190 shRNA (shE1A2, shABL and shBCR) at an MOI of 5, and the expression level of p190 was determined by western blot analysis. p190 Bcr-Abl expression were substantially suppressed (0.0-8.0%) by these three anti-p190 shRNAs (Figures 2a and b) . The expression of p145 Abl and p160 Bcr was substantially inhibited by shABL and shBCR, respectively (Figure 2a ).
Proliferation and survival of leukemia cell lines after the transduction of shRNAs
To investigate the biological consequences of anti-p190 shRNAs, p190
þ KOPN-30 cells, p210 þ K562 cells and p190/ p210 À NALM-6 cells were infected with lentiviral vectors encoding these shRNAs at an MOI of 5, and cell proliferation and viability were determined by trypan blue dye exclusion. The Ph þ ALL-derived KOPN-30 p190 þ cells ceased proliferation at two days after transduction with shE1A2, shABL and shBCR, and decreased in cell number and viability in a time-dependent manner, confirming that shRNA-mediated downregulation of p190 can kill Ph þ ALL cells (Figure 3 ). Given that shABL and shBCR would be expected to knock down both p190 and p210, we assessed the effect of these shRNAs in K562 cells, which express p210. As expected, shABL and shBCR eradicated the K562 cells, whereas shE1A2 did not have a notable effect, indicating that shE1A2 is sequence-specific to p190 (Figure 3) . To further confirm that RNAi-mediated downregulation is target sequence specific, we also transduced p190/p210 À NALM-6 cells. None of the anti-p190 shRNAs affected survival in NALM-6 cells, although shABL appeared to have some inhibitory effect on growth, which suggests that p145 Abl may be positively involved in NALM-6 cell proliferation.
The effect of shRNAs on imatinib-resistant cells
To determine whether anti-p190 shRNAs overcome imatinib resistance, murine Ba/F3 cells transformed with wild-type p190 or imatinib-resistant mutant (p190Y253H) were transduced with shE1A2, shABL and shBCR. In the absence of IL-3, these shRNAs depleted BaF/3 cells with both types of p190 in an equipotent manner (Figure 4 left) . Supplementation of IL-3 clearly rescued these cells from shRNA-mediated cytotoxic effects, suggesting that signal transduction machinery downstream of IL-3 receptor might be maintained irrespective of p190 expression (Figure 4 right).
The effect of downregulation of Abl and Bcr on normal hematopoiesis
We tested the effects of shABL and shBCR on cytokinedependent clonal growth and differentiation of normal CD34 þ cells. Figure 4b shows that shBCR did not influence colony 
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Bcr-Abl formation derived from colony-forming unit granulocyte-erythrocyte-monocyte-megakariocyte (CFU-GEMM), CFU granulocyte-monocyte (CFU-GM), and burst-forming unit erythroid (BFU-E) cells, but shABL markedly suppressed CFU-GEMM and BFU-E-derived colony formation.
The effect of Anti-p190 shRNA on p190 and the downstream signal transduction pathway Bcr-Abl kinase activates a number of signal transduction pathways, including the Jak/Stat, PI3K/Akt and Ras/Raf/MEK/ ERK pathways. 17 However, the relative contributions of these signaling pathways to p190-triggered proliferation and survival are not fully understood. To elucidate the primary event that is directly influenced by the downregulation of p190 Bcr-Abl, Ba/ F3-p190wt cells were transduced with anti-p190 shRNAs, and the phosphorylation status of molecules involved in Bcr-Ablmediated transformation was determined by immunoblot analysis at 48 h after transduction (Figure 5a ). There were no significant changes in phosphorylation status of Jak2 by the treatment with anti-p190 shRNAs. In contrast, a marked reduction in phosphorylated Stat5 was noted in anti-p190 shRNA-treated BaF/3-p190wt cells, supporting the idea that p190 activates Stat5 in a Jak2-independent manner. Anti-p190 shRNAs did not significantly affect phosphorylation of Akt or MEK1/2. These results imply that downregulation of p190 rapidly results in the inactivation of Stat5, but inactivation of either PI3K/Akt or Ras/Raf/MEK/ERK pathway is not significant compared with Stat5.
The effect of 17-AAG on p190 and the downstream signal transduction pathway
Treatment with 17-AAG disrupts Hsp90 function and degrades its client protein, p190/p210. 18, 19 Ba/F3-p190wt cells were treated with increasing concentrations of 17-AAG for 24 h, and þ cells were transduced with shRNA lentiviral vectors at an MOI of 20, and cytokine-dependent clonal growth was examined by the methylcellulose hematopoietic colony-forming assay. The number of various types of colonies was scored after 14 days in culture.
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Bcr-Abl the expression level and phosphorylation status of the same molecules shown in Figure 5a were analyzed. As shown in Figure 5b , 17-AAG downregulated both p190 and p145 Abl in a dose-dependent manner at concentrations 4300 nM. The Jak2 protein level was downregulated at 1000 nM. The downregulation of phosphorylated Stat5 preceded that of total Stat5 protein level, which was not affected by the treatment with 17-AAG up to 300 nM. Akt1 and MEK1/2 were downregulated by 17-AAG at around 300 nM. These results suggest that 17-AAG affects p190 as well as various molecules involved in Bcr-Abl-mediated transformation.
Combined effects between shRNA, imatinib and 17-AAG Because anti-p190 RNAi and 17-AAG can downregulate p190 by different mechanisms, and imatinib inactivates the kinase activity of p190, their combination may work in a synergistic or additive manner in killing of Ba/F3-p190wt and BaF/3-p190Y253H cells. These two cell lines were transduced with anti-p190 shRNAs in a suboptimal condition (MOI ¼ 1) and cultured with increasing dose of either imatinib or 17-AAG. Under these conditions, anti-p190 shRNAs increased sensitivity of Ba/F3-p190wt cells to imatinib and 17-AAG. BaF/3-p190Y253H cells did not respond to imatinib, even at 5 mM; however, the anti-p190 shRNAs appeared to restore sensitivity to higher concentrations of imatinib (Figure 6a ). On the other hand, anti-p190 shRNAs cooperated with 17-AAG to kill Ba/F3-p190Y253H cells, with a dose-response curve similar to that in Ba/F3-p190wt cells (Figure 6b) . When Ba/F3-p190 cells were exposed to various dosage combinations of 17-AAG and imatinib, the drugs acted synergistically to kill Ba/F3-p190wt cells, and 17-AAG clearly sensitized Ba/F3-p190Y253H cells to imatinib (Figure 6c) .
Discussion
We applied RNAi to test whether specific and efficient killing of Ph þ ALL cells could be achieved by downregulation of p190. Wohlbold et al. 15 first reported the effective inhibition of p190 protein by siRNA and its cytotoxicity in murine 32D-p190 cells; however, they induced siRNA by elecroporation, which is likely to cause nonspecific damage to recipient cells. We independently designed a series of overlapping shRNAs complementary to the e1a2 junction of p190 and determined the optimal target sequence for inhibition, finding a sequence identical to that described by Wohlbold et al. Use of lentiviral transfer of shRNA expression cassettes provided efficient transduction and sustained silencing of the target protein with reduced nonspecific damage. Using a similar vector system, Scherr et al.
14 have demonstrated that stable, but not transient, RNAi can efficiently deplete p210 from p210 þ cells, depending on the MOI used for infection; transduction at a high MOI resulted in almost complete loss of viable cells, but transduction at a low MOI caused minimal growth inhibition. These results are compatible with our data in Figures 4 and 6 .
We also showed that shBCR and shABL very efficiently downregulated p190/p210 Bcr-Abl proteins as well as their normal counterparts. Although Abl-deficient mice have multiple defects, including high postnatal mortality, runting and morphological abnormalities, Abl is considered to be dispensable for the function of hematopoietic stem cells, myeloid progenitor cells and immune cells. 20, 21 On the other hand, Bcr-null mice appear intact, and a peculiar finding is that their neutrophils show a marked increase in superoxide production upon activation. 22 Consistent with these findings, shABL slightly inhibited proliferation of p190/p210 À NALM-6 cells without loss of viability, but shBCR did not affect these cells. In addition, BaF/3-p190 cells treated with shABL and shBCR could be 
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Bcr-Abl rescued by exogenous IL-3, indicating that neither Abl nor Bcr is essential for response to IL-3. In addition, shABL, but not shBCR, inhibited CFU-GEMM/BFU-E-derived colony formation, which suggests that Abl plays a role especially in normal erythropoiesis. Furthermore, shABL, but not shBCR, profoundly depleted 293 cells during the culture of several days, suggesting the tissue-specific critical role of Abl (data not shown). Thus, it is possible that, with an improved delivery system such as our previously developed CD19-targeted liposomes, 23 anti-p190 shRNAs may become a therapeutic option in Ph þ ALL.
Hsp90 is a molecular chaperon that forms complexes with a variety of polypeptides and facilitates the initial folding and stabilization of its client proteins. Hsp90 is disrupted by 17-AAG, 24 which induces the degradation of p190/p210 18, 19 and thereby inhibits the proliferation of p190/p210 þ cells with or without the kinase domain mutation. 25 We revealed that 17-AAG downregulated p190 and other signaling molecules downstream of p190. Some studies have shown that anti-p210 siRNA in combination with imatinib or 17-AAG exerts more potent activity than control siRNA with imatinib or 17-AAG in 
Bcr-Abl p210 þ cells, with or without the kinase domain mutation. 12, 26 In addition, Radujkovic et al. 27 have shown that combination treatment with 17-AAG and imatinib inhibits cell proliferation additively/antagonistically in imatinib-sensitive p210 þ cells and synergistically in imatinib-resistant cells. Our results are closely compatible with these data, and combination-targeting strategies, as described here, may have enhanced therapeutic potency.
The activation of Stat5 in Ph þ leukemia cells is well recognized, 28, 29 but its significance in the pathogenesis of Ph þ leukemia is controversial. However, BCR-ABL-transduced hematopoietic progenitors from Stat5-null mice cannot generate leukemia in recipient mice, 30 and that anti-Stat5 siRNA impairs Ph þ myeloid colony formation in CML. 31 These two recent studies suggest that Stat5 contributes to Bcr-Abl-induced leukemogenesis. Bcr-Abl may directly activate Stat5 through phosphorylation, 32, 33 or may indirectly activate Stat5 through phosphorylation by Jak2 or Src family kinases, 28, 34, 35 both of which are activated in Bcr-Abl-expressing cells. Interestingly, tyrosine phosphorylation of Stat5 was substantially eliminated in BaF/3-p190wt cells transduced with anti-p190 shRNAs, whereas Jak2, Akt and MEK1/2 were still in an activated state. These results offer further evidence for the critical role of Stat5 in Bcr-Abl-induced transformation of hematopoietic cells. It is likely that p190 directly phosphorylates Stat5 and that Jak2 is remote from activation of Stat5 in this cell context, although the possible involvement of Src family kinases such as Hck and Lyn cannot be excluded. The mechanism by which phophorylation of several signal transducers was maintained after p190 downregulation remains to be elucidated. Nevertheless, compared with the PI3K/Akt and Ras/Raf/MEK/ERK pathways, the Stat5 signaling pathway contributes more closely to p190-mediated transformation of hematopoietic cells.
In conclusion, RNAi-mediated silencing of p190 is a promising tool for both signal transduction delineation and therapeutic application in p190-expressing leukemia.
